Visceral Leishmaniasis Market Size, Share & Demand Report By Treatment Type (Antimonial Drugs, Amphotericin B, Miltefosine, Combination Therapy), By Diagnosis Method (Parasitological Diagnosis, Serological Tests, Rapid Diagnostic Tests), By End-Use (Hospitals, Clinics, Community Healthcare Centers), By Region & Segment Forecasts, 2025–2034

Key Highlights

• Market size was estimated at USD 410 million in 2025 and is projected to reach USD 820 million by 2034. This reflects steady expansion supported by increasing diagnosis rates and improved treatment availability across endemic regions.
• The market is expected to grow at a CAGR of approximately 8.1% during the forecast period. This growth is driven by rising disease prevalence and continuous advancements in therapeutic approaches.
• Global health initiatives and funding for neglected tropical diseases are increasing significantly. These efforts are strengthening research, improving drug access, and enhancing disease management programs.
• The adoption of combination therapies is steadily increasing across treatment protocols. These therapies improve treatment efficacy, reduce resistance risks, and support better patient outcomes.

Market Trends

Increasing Adoption of Combination Therapies

The visceral leishmaniasis market is experiencing a shift toward combination therapies as healthcare providers aim to improve treatment effectiveness and reduce resistance risks. Traditional monotherapies are gradually being replaced with multi-drug regimens that offer higher cure rates and shorter treatment durations. This trend is particularly evident in regions with high disease burden, where resistance to first-line drugs has been reported. Combination therapies also help reduce treatment costs over time by minimizing relapse and hospitalization rates. Pharmaceutical companies are actively investing in research to develop safer and more efficient drug combinations, which is expected to further strengthen this trend across both public and private healthcare systems.

Expansion of Rapid Diagnostic Technologies

Another significant trend shaping the visceral leishmaniasis market is the growing adoption of rapid diagnostic tests (RDTs). These technologies enable early and accurate detection of the disease, especially in remote and resource-limited settings. The use of portable and easy-to-use diagnostic kits is improving screening coverage and facilitating timely treatment initiation. Governments and non-governmental organizations are increasingly incorporating RDTs into national disease control programs. This trend is enhancing disease surveillance and reducing diagnostic delays, which has a direct positive impact on treatment demand. Continued innovation in diagnostic accuracy and affordability is expected to support widespread adoption in the coming years.

Market Drivers

Rising Prevalence of Visceral Leishmaniasis in Endemic Regions

The increasing incidence of visceral leishmaniasis in regions such as South Asia, East Africa, and parts of Latin America is a primary driver of market growth. Factors such as poor sanitation, malnutrition, and limited access to healthcare contribute to the spread of the disease. Population displacement and climate change are also influencing the geographic distribution of sandfly vectors, leading to new outbreaks. As a result, there is a growing demand for effective treatment options and preventive measures. Governments are prioritizing disease control strategies, which include mass drug administration and vector control programs, thereby boosting market expansion.

Strong Support from Global Health Organizations

Global health organizations and international funding agencies are playing a significant role in driving the visceral leishmaniasis market. Initiatives aimed at eliminating neglected tropical diseases are increasing investments in research, diagnostics, and treatment programs. Partnerships between public and private entities are facilitating the development and distribution of affordable medications. These collaborations are also supporting capacity building in endemic regions by improving healthcare infrastructure and training medical professionals. The consistent flow of funding and policy support is enabling sustained market growth and encouraging innovation in treatment approaches.

Market Restraint

Limited Access to Healthcare and Treatment in Remote Areas

One of the major restraints affecting the visceral leishmaniasis market is the limited access to healthcare services in remote and underserved regions. Many affected populations live in rural areas with inadequate medical infrastructure, which restricts timely diagnosis and treatment. The lack of trained healthcare professionals and essential medical supplies further exacerbates the issue. Additionally, logistical challenges such as poor transportation networks hinder the distribution of medications. This limitation not only delays treatment but also increases the risk of disease progression and transmission. For example, in certain parts of sub-Saharan Africa, patients often rely on community health workers who may not have access to advanced diagnostic tools or effective therapies. Addressing these challenges requires coordinated efforts to strengthen healthcare systems and improve accessibility, which remains a critical barrier to market growth.

Market Opportunities

Development of Novel Drug Therapies

The ongoing need for safer and more effective treatments presents a significant opportunity for the visceral leishmaniasis market. Current therapies are often associated with side effects and lengthy treatment durations, which can impact patient compliance. Pharmaceutical companies are focusing on developing new drug candidates with improved safety profiles and shorter treatment cycles. Advances in biotechnology and drug delivery systems are enabling the creation of targeted therapies that enhance efficacy. These innovations are expected to address unmet medical needs and expand treatment options, thereby driving market growth.

Expansion of Public-Private Partnerships

Public-private partnerships offer substantial growth potential for the visceral leishmaniasis market. Collaborations between governments, non-profit organizations, and pharmaceutical companies are facilitating the development and distribution of affordable treatments. These partnerships are also supporting large-scale screening and awareness campaigns, which help identify and treat more patients. By leveraging combined resources and expertise, stakeholders can accelerate research and improve healthcare delivery in endemic regions. The increasing focus on collaborative approaches is expected to create new opportunities for market expansion and innovation.

Segmental Analysis

By Treatment Type

The treatment type segment is dominated by antimonial drugs, which accounted for approximately 42% of the market share in 2024. These drugs have been widely used as first-line treatments due to their established efficacy and availability. Despite concerns about toxicity, they remain a primary option in many endemic regions due to cost-effectiveness. Governments and healthcare providers continue to rely on these treatments as part of national disease control programs. The widespread use of antimonial drugs highlights their importance in managing visceral leishmaniasis, particularly in low-resource settings where alternative therapies may not be readily accessible.

Liposomal amphotericin B is the fastest-growing subsegment, expected to register a CAGR of around 9.2% during the forecast period. Its superior safety profile and high efficacy make it a preferred choice in many treatment protocols. The growing adoption of this therapy is driven by increased funding and subsidies from global health organizations, which help reduce treatment costs. Additionally, advancements in formulation and distribution are improving accessibility, making it a key growth driver in the treatment segment.

By Diagnosis Method

Parasitological diagnosis held the largest share of approximately 48% in 2024, as it is considered the gold standard for confirming visceral leishmaniasis. This method involves direct detection of the parasite and provides high accuracy. Healthcare facilities in endemic regions continue to rely on this approach despite its invasive nature. The dominance of parasitological diagnosis reflects its reliability and established use in clinical practice.

Rapid diagnostic tests are the fastest-growing subsegment, with a projected CAGR of 10.1%. Their ease of use and quick results make them ideal for remote and resource-limited settings. Governments and organizations are increasingly adopting these tests for large-scale screening programs. The growing emphasis on early detection and treatment is driving the adoption of rapid diagnostic technologies, which is expected to significantly impact market growth.

By End-Use

Hospitals accounted for the largest share of around 55% in 2024, as they serve as primary centers for diagnosis and treatment. The availability of advanced medical equipment and trained professionals makes hospitals the preferred choice for managing complex cases. Patients with severe symptoms often require hospitalization, which contributes to the dominance of this segment.

Clinics and community healthcare centers are the fastest-growing subsegment, with a CAGR of approximately 8.9%. These facilities play a crucial role in expanding healthcare access in rural and underserved areas. The increasing focus on decentralized healthcare delivery is driving the growth of this segment. Community-based programs and mobile clinics are improving diagnosis and treatment rates, which supports overall market expansion.

Regional Analysis

North America

North America accounted for a smaller share of the visceral leishmaniasis market in 2025, estimated at around 12%, due to lower disease prevalence. However, the region is expected to grow at a CAGR of approximately 6.5% during the forecast period. Growth is driven by increased research activities and funding for neglected tropical diseases. The presence of advanced healthcare infrastructure and strong regulatory frameworks supports innovation and clinical trials.

The United States dominates the regional market due to its robust research ecosystem and active involvement in global health initiatives. A unique growth factor is the increasing investment in drug development for rare and neglected diseases. Academic institutions and biotechnology firms are collaborating to develop new treatment options, which contributes to steady market growth despite low domestic disease incidence.

Europe

Europe held a market share of nearly 15% in 2025 and is projected to grow at a CAGR of 6.8% through 2034. The region benefits from strong support for global health programs and funding for infectious disease research. European countries are actively involved in initiatives aimed at controlling and eliminating neglected tropical diseases, which supports market expansion.

Germany leads the European market due to its advanced pharmaceutical industry and research capabilities. A key growth factor is the increasing focus on international collaborations to combat tropical diseases. European organizations are partnering with endemic countries to improve access to diagnostics and treatment, which enhances market growth and global outreach.

Asia Pacific

Asia Pacific dominated the visceral leishmaniasis market in 2025 with a share of approximately 38% and is expected to grow at a CAGR of 8.5%. The high disease burden in countries such as India and Bangladesh drives demand for treatment and diagnostic solutions. Government-led eradication programs and improved healthcare infrastructure further support market growth.

India is the leading country in the region due to its high prevalence of visceral leishmaniasis. A unique growth factor is the implementation of national elimination programs that focus on early diagnosis and treatment. These initiatives are improving healthcare access and reducing disease incidence, thereby supporting sustained market expansion.

Middle East & Africa

The Middle East & Africa region accounted for around 20% of the market share in 2025 and is projected to grow at a CAGR of 8.3%. The high prevalence of the disease in sub-Saharan Africa is a major factor driving market growth. Limited healthcare infrastructure poses challenges, but ongoing international support is helping improve access to treatment.

Sudan dominates the regional market due to its significant disease burden. A key growth factor is the increasing involvement of non-governmental organizations in providing medical support and resources. These efforts are enhancing diagnosis and treatment rates, which contributes to market growth despite infrastructural challenges.

Latin America

Latin America held a market share of approximately 15% in 2025 and is expected to grow at a CAGR of 7.2% during the forecast period. The presence of endemic regions and government initiatives to control the disease are driving market growth. Improved awareness and healthcare access are also contributing factors.

Brazil is the dominant country in the region due to its high incidence of visceral leishmaniasis. A unique growth factor is the expansion of vector control programs aimed at reducing disease transmission. These initiatives, combined with improved diagnostic capabilities, are supporting market development.

Competitive Landscape

The visceral leishmaniasis market is moderately fragmented, with a mix of global pharmaceutical companies and regional players. The top five companies include Gilead Sciences, Sanofi, Pfizer Inc., GlaxoSmithKline plc, and Novartis AG. Among these, Gilead Sciences is considered a leading player due to its strong portfolio of antifungal and antiparasitic drugs. The company has been actively involved in developing and distributing liposomal amphotericin B, which is widely used for treating visceral leishmaniasis.

Recent developments in the market include increased collaborations between pharmaceutical companies and global health organizations to improve drug accessibility. Companies are also focusing on expanding their presence in endemic regions through partnerships and distribution agreements. Continuous investment in research and development is enabling the introduction of new therapies and diagnostic solutions, which enhances competition and drives innovation in the market.

Key Players List

1. Gilead Sciences
2. Sanofi
3. Pfizer Inc.
4. GlaxoSmithKline plc
5. Novartis AG
6. Bayer AG
7. Merck & Co., Inc.
8. Johnson & Johnson
9. Cipla Ltd.
10. Sun Pharmaceutical Industries Ltd.
11. Lupin Limited
12. Aurobindo Pharma
13. Dr. Reddy’s Laboratories
14. Teva Pharmaceutical Industries Ltd.
15. Mylan N.V.

Recent Developments

• A major pharmaceutical company expanded its production capacity for liposomal amphotericin B to meet rising global demand.
• A public-private partnership launched a new initiative to improve access to rapid diagnostic tests in endemic regions.
• Regulatory authorities approved a new combination therapy aimed at reducing treatment duration and improving patient outcomes.